Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-11-01
|
| Series: | Oncology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40487-023-00249-0 |
| _version_ | 1797275461207719936 |
|---|---|
| author | Heidi Ko Rebecca A. Previs Kyle C. Strickland Jonathan Klein Brian Caveney Chiara Chiruzzi Marcia Eisenberg Eric A. Severson Shakti Ramkissoon Kamal S. Saini |
| author_facet | Heidi Ko Rebecca A. Previs Kyle C. Strickland Jonathan Klein Brian Caveney Chiara Chiruzzi Marcia Eisenberg Eric A. Severson Shakti Ramkissoon Kamal S. Saini |
| author_sort | Heidi Ko |
| collection | DOAJ |
| first_indexed | 2024-03-07T15:14:41Z |
| format | Article |
| id | doaj.art-13b6eb10453946f2ba69ec31662e4323 |
| institution | Directory Open Access Journal |
| issn | 2366-1070 2366-1089 |
| language | English |
| last_indexed | 2024-03-07T15:14:41Z |
| publishDate | 2023-11-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Oncology and Therapy |
| spelling | doaj.art-13b6eb10453946f2ba69ec31662e43232024-03-05T17:58:28ZengAdis, Springer HealthcareOncology and Therapy2366-10702366-10892023-11-01121131710.1007/s40487-023-00249-0Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?Heidi Ko0Rebecca A. Previs1Kyle C. Strickland2Jonathan Klein3Brian Caveney4Chiara Chiruzzi5Marcia Eisenberg6Eric A. Severson7Shakti Ramkissoon8Kamal S. Saini9Labcorp OncologyLabcorp OncologyLabcorp OncologyLabcorp OncologyLabcorp OncologyFortrea IncLabcorp OncologyLabcorp OncologyLabcorp OncologyFortrea Inchttps://doi.org/10.1007/s40487-023-00249-0HER2-lowMetastatic breast cancerHER2 testingHER2-directed antibody–drug conjugate |
| spellingShingle | Heidi Ko Rebecca A. Previs Kyle C. Strickland Jonathan Klein Brian Caveney Chiara Chiruzzi Marcia Eisenberg Eric A. Severson Shakti Ramkissoon Kamal S. Saini Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate? Oncology and Therapy HER2-low Metastatic breast cancer HER2 testing HER2-directed antibody–drug conjugate |
| title | Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate? |
| title_full | Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate? |
| title_fullStr | Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate? |
| title_full_unstemmed | Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate? |
| title_short | Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate? |
| title_sort | is her2 low a new clinical entity or merely a biomarker for an antibody drug conjugate |
| topic | HER2-low Metastatic breast cancer HER2 testing HER2-directed antibody–drug conjugate |
| url | https://doi.org/10.1007/s40487-023-00249-0 |
| work_keys_str_mv | AT heidiko isher2lowanewclinicalentityormerelyabiomarkerforanantibodydrugconjugate AT rebeccaaprevis isher2lowanewclinicalentityormerelyabiomarkerforanantibodydrugconjugate AT kylecstrickland isher2lowanewclinicalentityormerelyabiomarkerforanantibodydrugconjugate AT jonathanklein isher2lowanewclinicalentityormerelyabiomarkerforanantibodydrugconjugate AT briancaveney isher2lowanewclinicalentityormerelyabiomarkerforanantibodydrugconjugate AT chiarachiruzzi isher2lowanewclinicalentityormerelyabiomarkerforanantibodydrugconjugate AT marciaeisenberg isher2lowanewclinicalentityormerelyabiomarkerforanantibodydrugconjugate AT ericaseverson isher2lowanewclinicalentityormerelyabiomarkerforanantibodydrugconjugate AT shaktiramkissoon isher2lowanewclinicalentityormerelyabiomarkerforanantibodydrugconjugate AT kamalssaini isher2lowanewclinicalentityormerelyabiomarkerforanantibodydrugconjugate |